Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 10/20 | 0.43 |
| ▸ | CACNB4 | O00305 | 1/20 | 0.40 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNG3 | O60359 | 1/20 | 0.40 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.40 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.40 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.40 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.40 |
| ▸ | CACNG7 | P62955 | 1/20 | 0.40 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.40 |
| ▸ | CACNA1D | Q01668 | 1/20 | 0.40 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.40 |
| ▸ | CACNG1 | Q06432 | 1/20 | 0.40 |
| ▸ | CACNB2 | Q08289 | 1/20 | 0.40 |
| ▸ | CACNA1S | Q13698 | 1/20 | 0.40 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.40 |
| ▸ | CACNA1E | Q15878 | 1/20 | 0.40 |
| ▸ | CACNA2D4 | Q7Z3S7 | 1/20 | 0.40 |
| ▸ | CACNA2D3 | Q8IZS8 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4270173 | 1.00 | F10 (0.43) | F10CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4270872 | 1.00 | F10 (0.43) | F10CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL13608635 | 0.90 | F10 (0.46) | F10GPR6KIF18AIRAK4SYK | |
| SCHEMBL4274151 | 0.89 | F10 (0.45) | F10GPR6KIF18AIRAK4SYK | |
| SCHEMBL4274156 | 0.89 | F10 (0.45) | F10GPR6KIF18AIRAK4SYK | |
| SCHEMBL4269959 | 0.89 | CACNB4 (0.40) | F10CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4269962 | 0.89 | CACNB4 (0.40) | F10CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL4272904 | 0.89 | CACNB4 (0.40) | F10CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL13608650 | 0.88 | NPC1 (0.52) | F10CACNB4CACNA1ACACNA1GCACNG3 | |
| SCHEMBL14303443 | 0.88 | NPC1 (0.52) | F10CACNB4CACNA1ACACNA1GCACNG3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7615568-B2 | 3-[2-(cis-4-aminocyclohexyloxy)-4-methylsulfonylbenzoyl-amino]-N-(5-chloropyridin-2-yl)pyridine-2-carboxamide,; anticoagulant; platelet glycoprotein receptor antagonist; thrombosis; orally; acylation of amino-pyridine by (methylthio)benzoic acid followed by oxidation, alkylation, carbonylation | ELI LILLY AND COMPANY (US) | 2009-11-10 | — | — | US | disclosed |
| US-20080108594-A1 | Antithrombotic Ethers | ELI LILLY AND COMPANY (US) | 2008-05-08 | — | — | US | disclosed |
| EP-1644334-B1 | ANTITHROMBOTIC ETHERS | LILLY CO ELI (US) | 2008-01-02 | — | — | EP | disclosed |
| EP-1644334-A1 | ANTITHROMBOTIC ETHERS | Eli Lilly and Company (US) | 2006-04-12 | — | — | EP | disclosed |
| WO-2004108677-A1 | ANTITHROMBOTIC ETHERS | ELI LILLY AND COMPANY (US) | 2004-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108594-A1 | Antithrombotic Ethers | F11, SERPINC1, F2 | F10 16/4885CACNB4 2966/4885CACNA1A 1371/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.